Board of Directors


Matthew R. Stober

Mr. Matthew Stober joined Istari Oncology as President and Chief Executive Officer in January 2020. He brings more than 30 years of biopharmaceutical industry experience, leading multinational pharmaceutical organizations through significant transformational change, including the development and commercialization of dozens of breakthrough products, and the management of multiple strategic corporate transactions, including major acquisitions, carveouts and divestitures.

Prior to joining Istari, Mr. Stober led global operations as a corporate officer at pharmaceutical and medical technology companies, most recently as President of Operations at Smith and Nephew. Previously, he was a corporate officer and member of the executive committee at Hospira, where he managed 12,000+ global employees and led a turnaround at the company that resulted in a $17B acquisition by Pfizer. Prior to Hospira, he held global leadership positions at Novartis and GSK.

Mr. Stober earned a Bachelor of Science in chemical engineering from Villanova University. He currently serves on the Board of Directors for Istari Oncology and X-Vax Technology, as well as the Technical Advisory Board at Catalent Biologics.

Dani P. Bolognesi, PhD

Dr. Bolognesi is Chief Scientific Officer at Istari Oncology, Inc. and Professor Emeritus at Duke Medical Center, presently serving in a special capacity within Duke University Medical Center. He is chair of the Joint Steering Committee of MedBlue Incubator, Inc., an entity formed to identify and assist in the development of promising ideas, discoveries, innovations, and/or technologies from Duke faculty that have commercial potential.

His career spans all phases of drug development, and he has held a number of senior management positions. He was Founder, CEO and Chief Scientific Officer at Trimeris, Inc., a publicly traded biotechnology company that successfully obtained FDA approval for Fuzeon®, a first-in-class HIV fusion inhibitor, and he led the execution of its development and commercial collaboration with F. Hoffmann-La Roche AG. He also served as CEO and Chairman of b3Bio, Inc; CEO, Enci Therapeutics, Inc.; and CEO, C2 Regenerate, Inc.

Dr. Bolognesi’s scientific career spans three decades, during which he has held many positions at Duke University, including: James B. Duke Professor of Surgery, Professor of Microbiology/Immunology, Vice Chairman for Research and Development – Department of Surgery, Deputy Director of the Duke Comprehensive Cancer Center, and Director of the Duke University Center for AIDS Research. While at Duke, he and his research team contributed to the discovery of AZT (the first anti-HIV drug), identified the HIV protein targeted by fusion inhibitor drugs, and established a central laboratory that supported all HIV vaccine clinical trials sponsored by the National Institutes of Health. He also directed the NIH Central Laboratory for AIDS Vaccine Clinical Trials.

Robert R. Bonczek

Mr. Bonczek is Chief Administrative Officer at Istari Oncology, Inc. He is also President and Chief Financial Officer of MedBlue Incubator, Inc., and has served as President, Director, CFO and General Counsel of b3 bio, Inc.; CFO, General Counsel and Chief Administrative Officer of Trimeris, Inc.; and Chief Counsel and Global Director of Safety, Health and Environment, Dupont.

Mr. Bonczek is founding partner, Director and President of Aspen Tree Capital. He also serves on the boards of several other life science-related companies including NeurOp, Inc., Senex Biotechnology, Upstream Therapeutics, Inc., Deep Blue Medical Advances, Inc., Track X Technology, Cellective Biotherapy, Inc., and Istari Oncology, Inc.  He also serves on advisory boards for several companies, including Valence Advantage Life Sciences Fund, and Centre Partners. Mr. Bonczek received an AB in chemistry and a JD degree from the University of North Carolina. He also holds an MBA from the Wharton School at the University of Pennsylvania.

Raymond Cheong

Raymond Cheong, M.D., Ph.D. is a Principal at Baker Brothers Investments. Prior to joining Baker Brothers, Dr. Cheong completed an M.D. and a Ph.D. in Biomedical Engineering from Johns Hopkins University, where he was awarded the Michael A. Shanoff Award for best thesis research within the School of Medicine. Prior to Hopkins, he earned a B.S. in Chemical Engineering from the University of Maryland, College Park.

Sean P. Nolan

Sean P. Nolan served as President and Chief Executive officer and as a member of the Board of Directors of AveXis, Inc., from June 2015 to May 2018 when the company was acquired by Novartis. AveXis Inc. was a clinical-stage gene therapy company, dedicated to developing, manufacturing and commercializing novel treatments for patients suffering from rare and life-threatening neurological genetic diseases.

Prior to Joining AveXis, from February 2013 to April 2015, he was the chief business officer of InterMune, Inc., a biotechnology company later acquired by Roche Holding Ltd. While at InterMune, Mr. Nolan led multiple functions across the organization, including North American commercial operations, global marketing, corporate and business development and global manufacturing and supply chain. Mr. Nolan was also responsible for planning and executing the U.S. launch of InterMune’s treatment for idiopathic pulmonary fibrosis, a rare and fatal lung disease with no other approved treatments. Mr. Nolan served as chief commercial officer at Reata Pharmaceuticals, Inc. from August 2011 to December 2012, where he led the market strategy development and commercial planning for Reata Pharmaceuticals’ first in-class product pipeline. From September 2004 to November 2010, Mr. Nolan worked at Ovation Pharmaceuticals, Inc., a company focused on orphan neurology diseases. He held numerous management positions during that period including president of Lundbeck Inc., the U.S. affiliate. Ovation Pharmaceuticals was acquired by H. Lundbeck A/S in March 2009.

Mr. Nolan holds a B.A. in biology from John Carroll University. Mr. Nolan currently serves on the board of directors of Aquinox Pharmaceuticals, Inc and serves as Chairman of Encoded Therapeutics.

Victor Sandor MD.CM. FRCP(C)

Dr. Sandor has 18 years of experience in the pharmaceutical and biotechnology industries.  Prior to its acquisition by Pfizer, Dr. Sandor was Chief Medical Officer at Array BioPharma where he was instrumental in obtaining the approval of Braftovi and Mektovi for the treatment of BRAFV600E/K mutant melanoma and developing these products for the treatment of BRAFV600E colorectal cancer. Prior to joining Array, he was Senior Vice President for Global Clinical Development at Incyte Corporation where he played a critical role in the approval of Jakafi for the treatment of Myelofibrosis and Polycythemia Vera. Dr. Sandor was also Vice President and Chief Medical Officer for Oncology at Biogen Idec and held positions of increasing responsibility in oncology product development at AstraZeneca, where he played an important role in the registration of Arimidex (anastrozole) for adjuvant use and the development of several early stage programs through proof of concept. Dr. Sandor received his M.D.C.M. from McGill University in Montreal, Canada, and completed Fellowship in Medical Oncology at the National Institutes of Health in Bethesda, Maryland.